Skip to content
Adjuvance Technologies

Adjuvance Technologies

Empowering health.

  • About Us
  • Our Technology
  • Our Leadership
    • Board of Directors
    • Management Team
  • Investors & Media
  • Contact

Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

By jgardnerFebruary 18, 2015Publications
Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

Vaccine report concluding that QS-21 containing formulations of HBsAg induced high quality and persistent humoral and cellular immune responses that persisted at least 4 years after first vaccination in healthy adults.

leroux-roels_1-s2.0-S0264410X14014698-main

Post navigation

Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol
NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine

Recent Posts

  • ADJUVANCE PARTICIPATES IN THE BIO CEO AND INVESTORS CONFERENCE
  • ADJUVANCE PRESENTS ITS 2021 POTENTIAL AND PLANS AT THE BIOTECH SHOWCASE
  • ADJUVANCE TECHNOLOGIES ANNOUNCES NIH FUNDING FOR COVID-19 VACCINE RESEARCH
  • ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
  • Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
Copyright © All rights reserved. Theme Businessbiz by Sensational Theme